Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29879349 | 0.92 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL24740030 | 0.92 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL24738566 | 0.89 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL24738565 | 0.89 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL29879313 | 0.87 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3KLKB1 | |
| SCHEMBL29879413 | 0.87 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3KLKB1 | |
| SCHEMBL24739276 | 0.87 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3KLKB1 | |
| SCHEMBL24739278 | 0.87 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3KLKB1 | |
| SCHEMBL24737618 | 0.85 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3NPC1RAB9A | |
| SCHEMBL30997793 | 0.85 | KLKB1 (0.35) | SLC6A2SLC6A4SLC6A3KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | SLC6A2 3559/4885SLC6A4 3724/4885SLC6A3 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.